PD10-11 LONG-TERM FUNCTIONAL OUTCOMES AFTER ARTIFICIAL URINARY SPHINCTER (AMS 800®) IMPLANTATION IN FEMALE NEUROGENIC PATIENTS WITH STRESS URINARY INCONTINENCE

Abstract

You have accessJournal of UrologyUrodynamics/Incontinence/Female Urology: Neurogenic Voiding Dysfunction II1 Apr 2015PD10-11 LONG-TERM FUNCTIONAL OUTCOMES AFTER ARTIFICIAL URINARY SPHINCTER (AMS 800®) IMPLANTATION IN FEMALE NEUROGENIC PATIENTS WITH STRESS URINARY INCONTINENCE Véronique Phé, Priscilla Léon, Benjamin Granger, Morgan Rouprêt, Pierre Denys, Marc-Olivier Bitker, and Emmanuel Charttier-Kastler Véronique PhéVéronique Phé More articles by this author , Priscilla LéonPriscilla Léon More articles by this author , Benjamin GrangerBenjamin Granger More articles by this author , Morgan RouprêtMorgan Rouprêt More articles by this author , Pierre DenysPierre Denys More articles by this author , Marc-Olivier BitkerMarc-Olivier Bitker More articles by this author , and Emmanuel Charttier-KastlerEmmanuel Charttier-Kastler More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2015.02.951AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES The treatment of stress urinary incontinence (SUI) due to sphincter deficiency in neurogenic patients remains a real therapeutic challenge. There is no other treatment except surgery. Artificial urinary sphincter (AUS) is the last resort treatment of female SUI due to sphincter deficiency. Data are scarce regarding the long-term functional outcomes of AUS among female neurogenic patients. Our objective was to report the long-term functional outcomes of AUS implanted in female neurogenic patients suffering from SUI due to sphincter deficiency. METHODS Female neurogenic patients suffering from SUI due to sphincter deficiency and undergoing AUS (AMS 800®) implantation between 1986 and 2010 were included. Continence defined as no need for pads was assessed at the end of the follow-up. Kaplan–Meier survival curves estimated the survival rate of the device without needing explantation or revision. RESULTS Overall, 26 consecutive patients were included with a median age at surgery of 49.2 years (IQR 28.5-59.7). Among them, 23 had a spinal cord injury (all paraplegic) and 3 were spina bifida. Patients' baseline characteristics, types of devices implanted and postoperative complications are shown in table 1. The median follow-up was 7.5 years (IQR 3.9-23.8). The flowchart in figure 1 shows outcomes of the implanted devices. At the end of follow-up, 15 patients (57.7%) still had their primary AUS. The AUS was explanted in four women because of infection. Survival rates, without AUS explantation were 90%, 84%, 84% and 74% at 5, 10, 15, 20 years respectively. Survival rates without AUS revision were 75%, 51%, 51% and 51% at 5, 10, 15, 20 years respectively. At last follow-up, 71% of patients were continent. CONCLUSIONS In the long term, the AMS 800® can offer a high rate of continence to female neurogenic patients with SUI caused by sphincter deficiency, with a tolerable rate of explantation and revision. © 2015 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 193Issue 4SApril 2015Page: e204-e205 Advertisement Copyright & Permissions© 2015 by American Urological Association Education and Research, Inc.MetricsAuthor Information Véronique Phé More articles by this author Priscilla Léon More articles by this author Benjamin Granger More articles by this author Morgan Rouprêt More articles by this author Pierre Denys More articles by this author Marc-Olivier Bitker More articles by this author Emmanuel Charttier-Kastler More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...